

CR/PR, $p < 0.01$). Factors that did not affect prognosis include stage, lymphovascular space invasion, depth of invasion, mismatch repair status, performance status after recurrence, or adjuvant chemotherapy with initial radiation therapy.

Conclusions: Four prognostic factors may have utility in clinical practice to identify women who are less likely to respond to systemic chemotherapy. External validation of this predictive model is needed. Receipt of a prior radiosensitizer does not adversely affect response to subsequent chemotherapy following recurrence and should not be an exclusion factor for clinical trials evaluating systemic therapies.

doi:10.1016/j.ygyno.2019.03.212

Poster #23

High prevalence of BRCA deleterious mutations in African-American women with ovarian and/or breast cancer

K. Kennedy, K. Davis, W. Robinson. *Tulane University School of Medicine, New Orleans, LA*

Objectives: To determine the frequency of genetic mutations predisposing to breast and ovarian cancer (BRCA) in an African-American population of great genetic diversity, and to determine possible barriers to testing in that community.

Methods: As part of an ongoing Quality Improvement study, the records of women self-identified as African-American and diagnosed with and treated for breast and/or ovarian cancer from 2014–17 were examined to determine: 1) whether BRCA 1/2 testing was offered and/or accepted, 2) presence of deleterious mutations, 3) presence of variants of undetermined significance, 3) the timing of and reasons for testing in relation to treatment, 4) demographics.

Results: 56 women (42-Breast, 14-ovary) were identified as being diagnosed with breast and/or ovarian cancer in the study period, and had testing performed. 10/56 (17.8%) including 8 with breast cancer and 2 with ovarian cancer, had deleterious mutations. 4/56 (7.1%) (all breast) had variants of undetermined significance. No subjects who were offered testing declined. 27/56 subjects were diagnosed in 2014–2015, and of these, 3/27(11%) underwent testing prior to/during initial treatment. 29 subjects were diagnosed in 2016–17, and 27/29(93%) underwent testing prior to/during initial treatment. Reasons for deferring testing included lack of awareness and inability to pay for testing.

Conclusions: Hereditary predisposition to breast/ovarian cancer, as determined by BRCA 1–2 genetic testing, is more common than anticipated in this African-American population of high genetic diversity. The use of genetic testing in this population has been limited by lack of awareness and/or inability to pay for the test. Standard screening for and counseling regarding genetic cancer risk and testing should be performed in this population.

doi:10.1016/j.ygyno.2019.03.213

Poster #24

Assessing disease-related outcomes in morbidly obese endometrial cancer patients

K. Crean-Tate^a, M. Radeva^b, L. Me^b, M. AlHilli^a. ^aCleveland Clinic Gynecologic Oncology, Cleveland, OH. ^bCleveland Clinic Biostatistics, Cleveland, OH

Objectives: To evaluate the impact of morbid obesity on disease outcomes in women with low risk and high risk endometrial cancer (EC).

Methods: Patients diagnosed with EC from 1/1/2005–12/30/2015 were evaluated. Patients were stratified by body mass index (BMI) ($<$ or ≥ 40 kg/m²) and risk of recurrence (low risk (LR): stage 1–2, low or moderate grade, $< 50\%$ myometrial invasion and endometrioid type; high risk (HR): stage 3–4, high grade, $> 50\%$ myometrial invasion, or non-endometrioid). Patient demographics, tumor characteristics, and treatment-related outcomes were reviewed. Exclusion criteria included patients with benign disease, unknown characteristics needed for risk stratification, or BMI not available. Pearson chi-square test was used for categorical variable and ANOVA and Kruskal-Wallis for continuous factors. Analysis was performed using SAS.

Results: Out of 1775 patients included in the study, 1327 (74.8%) had a BMI < 40 and 448 (25.2%) were ≥ 40 . Patients with a BMI ≥ 40 were significantly younger (58.9 vs 64.2 yrs), more likely to have endometrioid histology (77.5% vs 67%), lower grade (52.5% vs 37.9%), earlier stage (78.5% vs 68.8% stage 1), myometrial invasion $< 50\%$ (65.8% vs 50.3%), and lower LVSI (23.0% vs 35.5%). Stratified by risk, LR patients with BMI ≥ 40 comprised 39% of the entire study population and were more likely to be younger, of black race, uninsured. Overall, 40% of LR patients underwent lymphadenectomy. Compared with patients with BMI < 40 , those with BMI ≥ 40 in the LR group were significantly less likely to undergo lymphadenectomy ($p < 0.0005$). Within the HR group, lymphadenectomy was performed in 72% of patients. Those with BMI ≥ 40 were significantly less likely to undergo lymphadenectomy ($p < 0.004$). There was no significant difference in risk of recurrence, patterns of recurrence, or disease specific survival between BMI ≥ 40 and BMI < 40 patients when stratified by risk group.

Conclusions: Morbid obesity is associated with favorable prognostic factors in patients with EC. When stratified by risk group, clinical and pathologic prognostic factors appeared to be equivalent among patients with BMI < 40 and those who are morbidly obese. Morbidly obese patients are less likely to undergo lymphadenectomy regardless of risk group. However, this does not appear to impact risk of recurrence or disease specific survival. Further evaluation of long term outcomes in this group of patients is warranted.

doi:10.1016/j.ygyno.2019.03.214

Poster #25

Multiple concurrent malignancies commonly seen in Immunocompetent Human Immunodeficiency Virus-infected women

K. Davis, W. Robinson. *Tulane University School of Medicine, Department of Obstetrics & Gynecology*

Objectives: To determine optimal surveillance strategies for Human Immunodeficiency Virus (HIV)-infected women with Human Papilloma Virus (HPV)-associated invasive and in situ malignancies.

Methods: All HIV-infected women diagnosed with an HPV-associated malignancy between 2011–2016 were identified and followed as part of an ongoing quality improvement project. The following data were collected: demographics, HIV treatment and response, malignancy treatment and response, and mortality. The data were summarized and compared using standard statistical tests.

Results: 17 HIV-infected women were identified with 2 or more HPV-related malignancy. The median age at time of diagnosis of initial malignancy was 31 years. 94% of the patients studied were African American. Invasive malignancies included cervix (9), vulva (7), anal (4), vagina (3), urethra/bladder (2), and oropharyngeal (3). In situ lesions included cervix (4), vulva (3), and oropharyngeal (1). Only 2 of the 17 patients had CD4 counts of less than 200 at time of initial diagnosis. Five of the 17 patients died, of whom all had a CD4 count

less than 200 at the time of death. Six of them had 3 separate malignancies.

Conclusions: Median age at time of diagnosis was significantly lower than that of the general population. HIV-infected women are at high risk for HPV-associated malignancies, even those who respond to antiretroviral therapy as measured by high CD4 levels and low viral loads. Multiple concurrent cancers are relatively common, even in patients with well-controlled HIV. Based on the data, survival was strongly correlated with response to antiretroviral therapy. However, multiple confounding factors may be present, emphasizing the need for further study. Careful cancer surveillance is critical and should be maintained, even in women who are responding to antiretroviral therapy. Similarly, oncologic encounters provide opportunities to reinforce the importance of adherence to antiretroviral therapy. Additionally, once a diagnosis of malignancy has been made, the level of vigilance in screening for other malignancies should increase.

doi:10.1016/j.ygyno.2019.03.215

Poster #26

Focal Adhesion Kinase (FAK) Regulation of Programmed Death-1 (PD-1)/Programmed Death Ligand-1 (PD-L1) checkpoint signaling in a mouse model of epithelial ovarian cancer

K. Taylor^a, X. Chen^b, I. Tancioni^a, E. Kleinschmidt^a, A. Barrie^a, C. Diaz-Osterman^a, G. Fu^b, A. Mark^a, G. Xu^a, K. Fisch^a, C. Xiao^c, D. Schlaepfer^a.
^aUniversity of California, San Diego, La Jolla, CA, USA. ^bXiamen University, Xiamen, Fujian, China. ^cThe Scripps Research Institute, La Jolla, CA, USA

Objectives: Our objectives were to create an aggressive mouse ovarian cancer model with genetic similarity to human high grade serous ovarian cancer (HGSOC); and to use this model to explore the effect of focal adhesion kinase (FAK) on tumor cell proliferation, leukocyte infiltration, and expression of PD-1 and PD-L1.

Methods: We previously derived the aggressive "ID8-IP" mouse ovarian cancer cell line from ID8 cells by intraperitoneal passage into an immunocompetent C57BL/6 mouse. Exome sequencing was used to determine deletions and copy number alterations (CNAs), and RNA sequencing was used to determine relative gene expression between the ID8 and ID8-IP cell lines. A FAK knockout cell line was generated ("ID8-IP FAK KO") using the CRISPR/Cas9 system, and a third cell line ("ID8-IP FAK re-expressing") was created by re-introducing FAK into "ID8-IP FAK KO" cells using lentiviral transduction. Tumor cells were injected intraperitoneally into C57BL/6 mice (n=8 per group), and tumor cell and immune cell populations among ascites-associated cells were identified using flow cytometry.

Results: Our ID8-IP cell line demonstrated several deletions and CNAs analogous to common genomic alterations in human HGSOC (Table 1). In particular, there were several alternate splice variants in the tumor suppressor p53 gene (Trp53), and no p53 protein detected in the ID8-IP cell line by Western blot. Using our mouse model, we found a higher proportion of tumor cells in the ID8-IP compared to the ID8-IP FAK KO (61.4% vs 24.4%, respectively; p<0.0001), and fewer leukocytes (19.9% vs 48.3%, p=0.0003). There were more PD-1 positive CD8+ T cells in the ID8-IP relative to the ID8-IP FAK KO (38.18% vs 14.26%, respectively; p=0.038). Similar trends were noted between the ID8-IP FAK re-expressing and ID8-IP FAK KO groups. In vitro, ID8-IP cells had more cell surface PD-L1 expression compared to ID8-IP FAK KO cells (81.4% vs 39.7%, respectively; p<0.0001), with the highest PD-L1 expression in the ID8-IP FAK re-expressing cells (88.5%).

Conclusions: We established a unique mouse ovarian cancer model with genetic similarity to human high grade serous ovarian cancer that allows for study of the immune microenvironment. Here, we

present a novel link between FAK and the PD-1/PD-L1 pathway in ovarian cancer. Ongoing studies will further explore the relationship between FAK and this immune checkpoint pathway, as well as other immune cell populations.

doi:10.1016/j.ygyno.2019.03.216

Poster #27

Incidence and implications of circulating tumor cells in endometrial cancer

L.E. Dockery, T.T. Tanaka, R. Zhang, C.L. Toal, C. Dinges, K.M. Moxley.
University of Oklahoma Health Sciences Center, Oklahoma City, OK

Objectives: Endometrial cancer is the most common gynecologic malignancy affecting women in the United States. Historically, 20-25% of patients with clinical stage I disease will have extrauterine disease at the time of surgery. These patients account for a large proportion of endometrial cancer related recurrences and deaths. Recently, the utility of surgical staging has been called into question by a series of prospective trials that have failed to demonstrate a survival benefit for comprehensive surgical staging. Currently, no biomarker exists to predict which patients are at risk for extrauterine disease at the time of presentation. Increasing numbers of circulating tumor cells (CTCs) have been linked to the ability to predict metastases in malignancies like breast cancer. This study aims to evaluate the ability of CTCs to serve as a biomarker for identifying women at risk of metastatic disease and need for comprehensive surgical staging.

Methods: A prospective cohort study was performed. Informed consent was obtained and 10mL of whole blood was collected from women with clinical stage I endometrial carcinoma of any tumor grade and histology. The CTCs were collected from the sample using an ISET device, fixed in duplicate on a porous membrane, stained with MGG, and identified and counted by a gynecologic pathologist. Clinical, demographic, and outcome data was abstracted from patient's electronic medical records. Summary statistics were used to describe demographic and clinical characteristics. Fisher's Exact Tests were used to assess associations between CTCs and clinical variables.

Results: 37 patients with clinical stage I endometrial cancer were included in the study. The majority of patients (59.5%, n=22) had IA disease following definitive surgical management. Eleven patients (29.7%) were found to have extrauterine disease following surgery. CTCs were identified in 48.7% of patients. There was no association between FIGO stage and presence of CTCs (p=0.5621). There was no association between tumor grade and presence of CTCs (p=0.6092). Additionally, there was no association between tumor histology and presence of CTCs (p=0.6943).

Conclusions: CTCs do not appear to be a reliable indicator of extrauterine disease among women with clinical stage I endometrial cancer. Further study is needed to develop predictive markers for those women requiring comprehensive surgical staging in this population.

doi:10.1016/j.ygyno.2019.03.217

Poster #28

Vitamin D, leptin, vitamin D receptor single nucleotide polymorphism and treatment-related morbidity in ovarian, primary peritoneal, and fallopian tube cancer

L.E. Dockery, J.M. Ward, S.K. Vesely, E. Thavathiru, D.M. Benbrook, K.N. Moore, L.L. Holman. The University of Oklahoma Health Sciences Center, Oklahoma City, OK